Business Wire

NeoTract Announces Results from Two Studies Demonstrating Transformative Benefits of the UroLift® System for BPH Care

Jaa

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company’s novel UroLift® System for patients with Benign Prostatic Hyperplasia (BPH).

“This analysis of the UroLift System demonstrates its transformative impact on BPH care within a major health system,” said Dave Amerson, president of the NeoTract Interventional Urology business unit. “These real-world results continue to support the safety and efficacy of the UroLift System findings of our pivotal trial, and also suggest that the adoption of the UroLift System can save health systems millions in reduced organizational costs when compared to the traditional invasive surgical TURP procedure for patients with BPH.”

U.K. Data Suggests UroLift System Greatly Reduces Costs Associated with TURP
The Transforming BPH Surgical Care study compares patient outcomes, resources consumed, and associated costs of treatment for BPH in men treated with the UroLift System compared to those who received TURP using Patient Level Information Costing System (PLICS) at the Leeds Teaching Hospitals NHS Trust in Leeds, England.

Data from this real-world study, presented by Oliver Kayes, M.D., urologist of Leeds Teaching Hospitals NHS Trust, shows that treatment of BPH with the UroLift System shortens operation time while also reducing patients’ hospital stay to an average of 0.4 days, compared to 4.6 days for acute TURP and 1.8 days for elective TURP. Results from this study demonstrate that BPH treatment with the UroLift System reduced overall costs by 42% when compared to the TURP surgery. Further analysis from the single-center study calculates that adoption of the UroLift System for 50% of all BPH surgeries at the hospital would generate an additional annual savings of £42,000, while also saving 300 bed days and 106 hours of operating theatre time each year.

“The results of this study demonstrate that the UroLift System moves BPH procedures into day-case settings, achieving positive patient outcomes without financial investment or increased complications in patients with BPH,” said Dr. Kayes. “Data from this study also suggests that adoption of the UroLift System would increase overall capacity, allowing for healthcare centers to focus on critical cancer targets and waiting times, while reducing delays in both urgent and non-urgent surgery.”

The Cost Reductions study, also presented by Dr. Kayes, compares outcomes and cost following treatment with the UroLift System or TURP. The study analyzed reports on the UroLift System from 2010 onwards, as well as data from the National Health Service Hospital Episode Statistics (HES) database and The Health Improvement Network (THIN) to identify hospitalization and treatment rates for TURP from 2010 to 2016 in England.

The results indicate that the average procedure costs are similar with the UroLift System or TURP, but no hospital stay or follow-up visits are required with the UroLift System. The analysis also accounted for the lower rate of complications with the UroLift System based on published data, which includes minimal need for hospital treatment and no instances of new, sustained erectile or ejaculatory dysfunction. With a conservative estimate of 50% reduction in complications using the UroLift System and 50% adoption in patients who would otherwise undergo a TURP procedure, this analysis indicates that approximately £27 million could be saved by reductions in complications alone. The results from this study are consistent with the Surgical Care study, demonstrating that an increased use of the UroLift System to treat patients with BPH could significantly reduce costs and maintain positive patient outcomes.

About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function. Patients also experienced a significant improvement in quality of life. Nearly 70,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The UroLift System Prostatic Urethral Lift procedure is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at www.UroLift.com.

About NeoTract | Teleflex Interventional Urology
A wholly owned subsidiary of Teleflex Incorporated, the NeoTract Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function. Learn more at www.NeoTract.com.

About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

Oliver Kayes is a paid consultant to NeoTract | Teleflex Interventional Urology.

###

MAC00843-03 Rev A

Contact information

For Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610.948.2836
or
Media:
Nicole Osmer
650.454.0504
nicole@healthandcommerce.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Prince Khalid bin Abdul Aziz bin Ayyaf Announces Launch of the 33rd Edition of Al Janadria Festival Next Thursday17.12.2018 18:46Tiedote

His Highness Prince Khalid Bin Abdul Aziz bin Ayyaf, Minister of National Guard and Chairman of the Supreme Committee of the National Festival of Heritage and Culture – Janadria, announced the launch of the 33rd Edition of the festival on Thursday under the patronage of the Custodian of the Two Holy Mosques King Salman bin Abdul Aziz. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005518/en/ His Highness Prince Khalid Bin Abdul Aziz bin Ayyaf, Minister of National Guard and Chairman of the Supreme Committee of the National Festival of Heritage and Culture – Janadria (Photo: AETOSWire) This was announced during a press conference held yesterday in Riyadh in the presence of the Special Envoy of the Indonesian President for the Middle East, Dr. Alwi Shihab, the Ambassador of the Republic of Indonesia in the Kingdom Agus Abi Jibril, the President of the Saudi Press Agency Abdullah Al Hussein and a crowd of representatives

Brightree Acquires Mobile Delivery Provider Apacheta to Streamline HME Delivery17.12.2018 17:05Tiedote

Brightree, a leading provider of cloud-based software helping out-of-hospital providers improve business performance and patient outcomes, today announced it has acquired privately held mobile delivery and cloud-based software-as-a-service (SaaS) provider Apacheta Corporation, further expanding the SaaS portfolio of Brightree’s owner, ResMed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005121/en/ The terms of the transaction were not disclosed. Apacheta offers mobile applications that empower companies to automate and streamline business processes in route sales, field marketing, pick-up and delivery, transportation and field services. Apacheta and its Media, PA-based employees will join Brightree, whose platform it has been integrated with since 2015. A secure mobile delivery module for ordering and tracking medical equipment was the number one feature request of HMEs in a recent customer satisfaction survey. Brigh

Transphorm’s High Voltage GaN FETs Amp Up Marotta Controls’ Military Grade High Frequency Power Supply17.12.2018 17:00Tiedote

Transphorm Inc.—the leader in the design and manufacturing of the highest reliability and first JEDEC- and AEC-Q101 qualified gallium nitride (GaN) semiconductors—today announced with Marotta Controls that the Aerospace and Defense supplier’s upcoming power supply unit (PSU) replaces incumbent Silicon (Si) MOSFETs with high voltage GaN PQFN devices to offer advanced benefits. Marotta’s latest design operates at high frequency in a conduction-cooled mechanically constrained envelope. The supply’s topology features hard switching and an automatic transformer RESET capability where transistor voltage stresses are clamped to the input voltage. The GaN devices increase the PSU’s efficiency dramatically and alleviate a complex thermal design in the small form factor package. “The demand on our power supplies and expectation of performance is high,” explained Mike Scruggs, Principal Engineer, Marotta Controls. “This particular complex PSU needed to reliably convert and distribute power in a s

Celgene Corporation Announces Celgene Cancer Care Links™ Program Grant Recipients17.12.2018 15:30Tiedote

Celgene Corporation (NASDAQ:CELG) today announced ten programs selected for funding under its Celgene Cancer Care Links™ program, an initiative designed to support cancer healthcare capacity building in resource-constrained countries around the world. The programs selected are expected to support established institutions partnering with in-country medical centers that provide essential cancer care services including awareness and education, prevention, diagnosis and care. The Celgene Cancer Care Links program is an initiative of Celgene Global Health, which focuses on healthcare challenges facing patients in developing parts of the world. “Celgene Cancer Care Links is another program we have created to make a meaningful impact for patients and healthcare systems around the world,” said Mark J. Alles, Chairman and Chief Executive Officer of Celgene. “We are excited to announce the first round of grants through this initiative and wish these world-renowned organizations and institutions

Ras Al Khaimah Marks New Year’s Eve with Amazing Fireworks and New Guinness World Record Bid17.12.2018 14:14Tiedote

This New Year’s Eve, Ras Al Khaimah is the place to be as the Emirate readies to host the most spectacular celebration with a 12-minute fireworks display - the bid for a new Guinness World Record display - and an array of family-oriented activities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005309/en/ Marjan, Ras Al Khaimah’s master-developer of freehold projects, will manage the show to mark 2019 with a glittering array of activities that will entertain all at its flagship development, Al Marjan Island. With three additional viewing areas around Al Marjan Island, New Year’s Eve in Ras Al Khaimah has fun and thrills in store for local and international visitors. Abdulla Al Abdouli, Managing Director & CEO of Marjan, said: “This year, we are offering exciting family activities that will delight all in the run-up to the amazing fireworks display that aims to set a new Guinness World Record. The event will position t

Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m Equity Investment17.12.2018 12:52Tiedote

Mobidiag Ltd., a commercial stage molecular diagnostics company addressing the spread of antimicrobial resistance, today announces that it has entered into a joint venture (‘JV’) agreement with Autobio Diagnostics (‘Autobio’), one of the leading clinical diagnostics companies in China, to commercialise the Novodiag® platform in China. In addition, Mobidiag announces that it has secured a separate €10m equity investment from Autobio. Lynx Financial (HK) Ltd, served as the exclusive financial advisor to Mobidiag in this transaction. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181217005272/en/ Mobidiag and Autobio will jointly invest €12.3m to establish a joint venture company in China. Autobio will invest €8m in cash to hold 65%, and Mobidiag will invest €4.3m to hold 35%. Mobidiag will grant to the JV an exclusive license for human infectious disease assays (except for sepsis) for China. Initial activities of the JV will i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme